Compare Citius Pharmaceuticals Inc (CTXR) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Remitly Global Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Remitly Global Inc trades at $23.73 (market cap $4.87B). The key difference: Remitly Global Inc is far larger — about 260× Citius Pharmaceuticals Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | RELY | |
|---|---|---|
Market Cap | $18.73M | $4.87B |
Sector | Health | Technology |
52-Week High | $1.82 | $25.93 |
52-Week Low | $0.48 | $12.20 |
Enterprise Value | $14.95M | $4.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
RELY stock trades at $24.42, down 5.82% over 24 hours, but maintains strong bullish technical signals with support at $24 and resistance at $26. The company demonstrates impressive fundamental momentum with Q2 2026 EPS of $0.93 beating expectations by 650% and revenue growth accelerating to 20% year-over-year. Recent initiatives include the Global Card launch and UAE licensing expansion, positioning for continued market share gains in the $800 billion remittance market.
With 92% analyst buy ratings and a $31 consensus price target implying 27% upside, RELY presents compelling growth potential. Key risks include execution challenges in new product launches and competitive pressure in digital payments. The stock's valuation at 17.56x P/E appears reasonable given 32.25% ROE and projected 16.85% net margins for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
